Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
42.3M
-
Number of holders
-
149
-
Total 13F shares, excl. options
-
40.1M
-
Shares change
-
+899K
-
Total reported value, excl. options
-
$1.09B
-
Value change
-
+$12.5M
-
Put/Call ratio
-
21.32
-
Number of buys
-
91
-
Number of sells
-
-74
-
Price
-
$27.18
Significant Holders of Tarsus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (TARS) as of Q2 2024
192 filings reported holding TARS - Tarsus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share as of Q2 2024.
Tarsus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (TARS) has 149 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 40.1M shares
of 42.3M outstanding shares and own 94.79% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (3.41M shares), BlackRock Inc. (3.27M shares), Paradigm Biocapital Advisors LP (2.44M shares), TANG CAPITAL MANAGEMENT LLC (2.25M shares), COWEN AND COMPANY, LLC (2.2M shares), VANGUARD GROUP INC (1.99M shares), MORGAN STANLEY (1.88M shares), Frazier Life Sciences Management, L.P. (1.59M shares), JENNISON ASSOCIATES LLC (1.48M shares), and PERCEPTIVE ADVISORS LLC (1.3M shares).
This table shows the top 149 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.